KR20250107292A - 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 - Google Patents

기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 Download PDF

Info

Publication number
KR20250107292A
KR20250107292A KR1020257022014A KR20257022014A KR20250107292A KR 20250107292 A KR20250107292 A KR 20250107292A KR 1020257022014 A KR1020257022014 A KR 1020257022014A KR 20257022014 A KR20257022014 A KR 20257022014A KR 20250107292 A KR20250107292 A KR 20250107292A
Authority
KR
South Korea
Prior art keywords
formula
patient
bronchiectasis
compound
oxazepane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257022014A
Other languages
English (en)
Korean (ko)
Inventor
라이닐데 헤이르만
유진 설리반
한스 롤랜드 론
스티븐 콘놀리
스티븐 스왈로우
카를로스 페르난데즈
Original Assignee
인스메드 인코포레이티드
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스메드 인코포레이티드, 아스트라제네카 아베 filed Critical 인스메드 인코포레이티드
Publication of KR20250107292A publication Critical patent/KR20250107292A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257022014A 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 Pending KR20250107292A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662368400P 2016-07-29 2016-07-29
US62/368,400 2016-07-29
PCT/US2017/044343 WO2018022978A1 (en) 2016-07-29 2017-07-28 Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
KR1020247018419A KR20240091302A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018419A Division KR20240091302A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드

Publications (1)

Publication Number Publication Date
KR20250107292A true KR20250107292A (ko) 2025-07-11

Family

ID=61011892

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020257022014A Pending KR20250107292A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR1020247018419A Ceased KR20240091302A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR1020197005469A Ceased KR20190035781A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR1020237011948A Ceased KR20230054480A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247018419A Ceased KR20240091302A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR1020197005469A Ceased KR20190035781A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR1020237011948A Ceased KR20230054480A (ko) 2016-07-29 2017-07-28 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드

Country Status (6)

Country Link
US (6) US20180028541A1 (https=)
EP (1) EP3490566A4 (https=)
JP (3) JP2019522039A (https=)
KR (4) KR20250107292A (https=)
CN (1) CN109789150A (https=)
WO (1) WO2018022978A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
US20210252015A1 (en) * 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN116157687A (zh) 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
WO2022232420A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937B (zh) * 2021-12-23 2026-04-10 杭州邦顺制药股份有限公司 二肽基肽酶ⅰ抑制剂及其用途
EP4450497A4 (en) * 2022-01-11 2025-11-26 Shanghai Yidian Pharmaceutical Tech Development Co Ltd NITRILE PEPTIDYL COMPOUND AND ITS USES
EP4479059A4 (en) * 2022-02-16 2026-01-28 Insmed Inc CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
JP2026510407A (ja) * 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物
KR102951779B1 (ko) 2023-08-31 2026-04-14 서울대학교병원 비결핵항산균 질환 및 기관지확장증의 진단을 위한 바이오마커 조성물
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases
WO2025250560A1 (en) * 2024-05-28 2025-12-04 Insmed Incorporated Methods for treating bronchiectasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
CN102574830A (zh) * 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
JP6473738B2 (ja) * 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
NO2699580T3 (https=) * 2014-01-24 2018-02-24
SMT202000516T1 (it) * 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
CA2965566A1 (en) * 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물

Also Published As

Publication number Publication date
US20200179398A1 (en) 2020-06-11
US20180028541A1 (en) 2018-02-01
EP3490566A1 (en) 2019-06-05
KR20190035781A (ko) 2019-04-03
CN109789150A (zh) 2019-05-21
EP3490566A4 (en) 2020-03-11
KR20230054480A (ko) 2023-04-24
US20190091236A1 (en) 2019-03-28
JP2025000959A (ja) 2025-01-07
KR20240091302A (ko) 2024-06-21
WO2018022978A1 (en) 2018-02-01
US20220133737A1 (en) 2022-05-05
US20240041896A1 (en) 2024-02-08
JP2019522039A (ja) 2019-08-08
US20250228870A1 (en) 2025-07-17
JP2022115951A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP2025000959A (ja) 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
US11975005B2 (en) Treatment of respiratory diseases
CA3089240A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
ZA200600411B (en) Methods of treating COPD and Pulmonary Hypertension
US20220281846A1 (en) Compounds and compositions for the treatment of respiratory diseases
CA3215375A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
US20220380343A1 (en) Compounds for the treatment of respiratory diseases
JP5555255B2 (ja) 呼吸器疾患の治療のためのスルホンアミド化合物
WO2025250560A1 (en) Methods for treating bronchiectasis
HK40058742B (zh) 呼吸性疾病的治疗
HK40023875B (en) Compounds for the treatment of respiratory diseases
HK40023875A (en) Compounds for the treatment of respiratory diseases

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R15-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000